CN112703014A - Egfr突变型癌症的治疗 - Google Patents

Egfr突变型癌症的治疗 Download PDF

Info

Publication number
CN112703014A
CN112703014A CN201980060618.8A CN201980060618A CN112703014A CN 112703014 A CN112703014 A CN 112703014A CN 201980060618 A CN201980060618 A CN 201980060618A CN 112703014 A CN112703014 A CN 112703014A
Authority
CN
China
Prior art keywords
ret
inhibitor
egfr
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980060618.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·哈塔
L·塞奎斯特
B·B·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cable Chart Pharmaceutical Co
General Hospital Corp
Original Assignee
Cable Chart Pharmaceutical Co
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cable Chart Pharmaceutical Co, General Hospital Corp filed Critical Cable Chart Pharmaceutical Co
Publication of CN112703014A publication Critical patent/CN112703014A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980060618.8A 2018-08-10 2019-08-09 Egfr突变型癌症的治疗 Pending CN112703014A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862717480P 2018-08-10 2018-08-10
US62/717,480 2018-08-10
US201862735730P 2018-09-24 2018-09-24
US62/735,730 2018-09-24
PCT/US2019/045919 WO2020033838A2 (en) 2018-08-10 2019-08-09 Treatment of egfr-mutant cancer

Publications (1)

Publication Number Publication Date
CN112703014A true CN112703014A (zh) 2021-04-23

Family

ID=69415686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980060618.8A Pending CN112703014A (zh) 2018-08-10 2019-08-09 Egfr突变型癌症的治疗

Country Status (5)

Country Link
US (1) US20210308134A1 (enExample)
EP (1) EP3833372A4 (enExample)
JP (1) JP7490635B2 (enExample)
CN (1) CN112703014A (enExample)
WO (1) WO2020033838A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116440136A (zh) * 2023-04-17 2023-07-18 浙江大学智能创新药物研究院 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EP4157230A1 (en) * 2020-05-29 2023-04-05 Blueprint Medicines Corporation Pralsetinib pharmaceutical compositions
EP4157829A1 (en) * 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
WO2022046867A1 (en) * 2020-08-25 2022-03-03 Loxo Oncology, Inc. Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers
CN116867492A (zh) * 2020-11-20 2023-10-10 赫尔森保健股份公司 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN113143931A (zh) * 2021-04-16 2021-07-23 南方医科大学 甲磺酸奥西替尼在制备寻常型银屑病治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077921A2 (en) * 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
CN103764676A (zh) 2011-08-04 2014-04-30 日本国立癌症研究中心 Kif5b基因和ret基因的融合基因、以及以该融合基因为目标的判断癌症治疗有效性的方法
BR112014004213A2 (pt) 2011-08-23 2017-06-20 Found Medicine Inc novas moléculas de fusão kif5b-ret e usos das mesmas
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ｒｅｔ融合体の検出法
EP2878672A4 (en) 2012-07-26 2016-02-17 Nat Cancer Ct FUSIONSGEN OF CEP55-GEN AND RET-GEN
CN105658814A (zh) 2013-08-20 2016-06-08 日本国立癌症研究中心 在肺癌中检测出的新型融合基因
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
MA43416A (fr) * 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
MX379513B (es) * 2016-04-01 2025-03-11 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US10934300B2 (en) 2017-06-23 2021-03-02 San Diego State University (Sdsu) Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
WO2019008172A1 (en) 2017-07-07 2019-01-10 Nipd Genetics Public Company Limited ENRICHED MULTIPLEXED PARALLEL ANALYSIS IN TARGET FOR TUMOR BIOMARKER EVALUATION
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077921A2 (en) * 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER DRILON等: "Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes", 《NAT REV CLIN ONCOL.》 *
KAREN L. RECKAMP等: "Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A Califor", 《JOURNAL OF CLINICAL ONCOLOGY》 *
SAMUEL J. KLEMPNER等: "Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI", 《LUNG CANCER》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116440136A (zh) * 2023-04-17 2023-07-18 浙江大学智能创新药物研究院 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用
CN116440136B (zh) * 2023-04-17 2024-02-09 浙江大学智能创新药物研究院 甲磺酸阿美替尼在制备治疗乐伐替尼心脏毒性药物中的应用

Also Published As

Publication number Publication date
EP3833372A2 (en) 2021-06-16
JP7490635B2 (ja) 2024-05-27
US20210308134A1 (en) 2021-10-07
EP3833372A4 (en) 2022-06-08
WO2020033838A3 (en) 2020-03-19
JP2021534129A (ja) 2021-12-09
WO2020033838A2 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CN112703014A (zh) Egfr突变型癌症的治疗
Fu et al. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Drilon et al. A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105
JP7712990B2 (ja) 血小板由来成長因子受容体アルファの遺伝的異常に関連する癌の治療のための、１－［４－ブロモ－５－［１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル］－２－フルオロフェニル］－３－フェニルウレアおよびアナログの使用
Maron et al. Targeted therapies for targeted populations: anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma
Seiwert et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
Tartarone et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
Pal et al. Targeted therapies for non–small cell lung cancer: an evolving landscape
KR20210126653A (ko) Tno155 및 리보시클립을 포함하는 약제학적 조합물
Nishio et al. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Tan et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer
Casaluce et al. Resistance to crizotinib in advanced non-small cell lung cancer (NSCLC) with ALK rearrangement: mechanisms, treatment strategies and new targeted therapies
CA3231608A1 (en) Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
KR20220024540A (ko) 암 환자에서의 항종양 면역의 증진을 위한 환자 선택
US20250375452A1 (en) Sotorasib dosing regimen
RS65127B1 (sr) Ret inhibitor za primenu u lečenju kancera koji ima ret alteraciju
CN113164779A (zh) 治疗cdk4/6抑制剂耐药性癌症的方法
JP2024528705A (ja) がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法
JP2022515128A (ja) がんの処置のための併用療法
WO2024222902A1 (en) Methods of treating tki-resistant and sdh-deficient gist
HK40044366A (en) Treatment of egfr-mutant cancer
US20230124366A1 (en) Cancer treatment using fgfr inhibitors and plk1 inhibitors
WO2025201518A1 (en) Methods of treating tki-resistant and sdh-deficient gist
US20250339412A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
Pender et al. Understanding lung cancer molecular subtypes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044366

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210423

WD01 Invention patent application deemed withdrawn after publication